Today’s Rating Change: Worse Rating Was Given to Nivalis Therapeutics (NVLS) By a Broker. $3.0 is The Target

November 29, 2016 - By olga

Today's Rating Change:  Worse Rating Was Given to Nivalis Therapeutics (NVLS) By a Broker. $3.0 is The Target

Nivalis Therapeutics (NVLS) Downgrade

Robert W. Baird decreased shares of Nivalis Therapeutics (NVLS) from a “Outperform” rating to a “Neutral” rating in a an analyst report revealed to clients on Tuesday, 29 November. The firm from today has $3.0 TP on the stock.

The stock decreased 0.48% or $0.03 during the last trading session, hitting $6.25. About 10,950 shares traded hands. Nivalis Therapeutics Inc (NVLS) has risen 39.51% since April 26, 2016 and is uptrending. It has outperformed by 34.25% the S&P500.

Analysts await Nivalis Therapeutics Inc (NASDAQ:NVLS) to report earnings on March, 6. They expect $-0.58 earnings per share, down 38.10% or $0.16 from last year’s $-0.42 per share. After $-0.48 actual earnings per share reported by Nivalis Therapeutics Inc for the previous quarter, Wall Street now forecasts 20.83% negative EPS growth.

Nivalis Therapeutics, Inc. is a clinical-stage pharmaceutical company. The company has a market cap of $97.61 million. The Firm discovers, develops and commercializes product candidates for patients with cystic fibrosis . It currently has negative earnings. It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.

According to Zacks Investment Research, “Nivalis Therapeutics, Inc. is a pharmaceutical company. The company is engaged in discovery, development and commercialization of molecule therapeutics for cystic fibrosis. Nivalis Therapeutics, Inc. is headquartered in Boulder, Colorado.”

NVLS Company Profile

Nivalis Therapeutics, Inc., incorporated on March 30, 2007, is a clinical-stage pharmaceutical company. The Firm discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). The Firm focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases. The Firm operates through discovering and development of potential drugs segment. The Company’s activities are focused on discovery and development of its portfolio of GSNOR inhibitors, including N91115. GSNOR inhibitor portfolio includes other compounds with differing chemical structures and properties suitable for oral, inhaled, injectable and topical administration. The Company’s drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.

More recent Nivalis Therapeutics Inc (NASDAQ:NVLS) news were published by: Rttnews.com which released: “Nivalis Therapeutics Inc. (NVLS) Is Losing Ground After Phase 2 Study Failed” on November 28, 2016. Also Marketwatch.com published the news titled: “/quotes/zigman/3870025/realtime” on July 13, 2009. Globenewswire.com‘s news article titled: “Nivalis Therapeutics Announces Pricing of Its Initial Public Offering” with publication date: June 17, 2015 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>